Drug/indication:Acetadote for non-acetaminophen acute liver failure
Approval decision date: December 2010
Recent stock performance: At $4.92, stock is trading at its lows for the year.The FDA review was extended three months beyond its original August approval date.
Orexigen Therapeutics (OREX - Get Report) Drug/indication: Contrave for obesity FDA advisory panel: Dec. 7, 2010 Approval decision date: Jan. 31, 2011 Recent stock performance: At 4.73, the stock is starting to lift off its July low of $3.81. Orexigen is the third company, after Vivus and Arena, to bring its obesity drug in front an FDA advisory panel.
Human Genome Sciences Drug/indication: Benlysta for lupus Approval decision date: Dec. 9, 2010 If approved, Benlysta would be the first new drug for lupus patients in 50 years. GlaxoSmithKline will co-market Benlysta.